Presentation is loading. Please wait.

Presentation is loading. Please wait.

Salvage surgery for advanced non–small cell lung cancer after response to gefitinib  Tomoyuki Hishida, MD, Kanji Nagai, MD, Tetsuya Mitsudomi, MD, Kohei.

Similar presentations


Presentation on theme: "Salvage surgery for advanced non–small cell lung cancer after response to gefitinib  Tomoyuki Hishida, MD, Kanji Nagai, MD, Tetsuya Mitsudomi, MD, Kohei."— Presentation transcript:

1 Salvage surgery for advanced non–small cell lung cancer after response to gefitinib 
Tomoyuki Hishida, MD, Kanji Nagai, MD, Tetsuya Mitsudomi, MD, Kohei Yokoi, MD, Haruhiko Kondo, MD, Hirohisa Horinouchi, MD, Hirohiko Akiyama, MD, Takeshi Nagayasu, MD, Masahiro Tsuboi, MD  The Journal of Thoracic and Cardiovascular Surgery  Volume 140, Issue 5, Pages e69-e71 (November 2010) DOI: /j.jtcvs Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions

2 Figure 1 A, Overall survival curve of patients who underwent surgical resection after response to gefitinib administration. Median overall survival after surgery was 32 months. B, Recurrence-free survival curve of patients who underwent surgical resection after response to gefitinib administration. Median recurrence-free survival after surgery was 6 months. The Journal of Thoracic and Cardiovascular Surgery  , e69-e71DOI: ( /j.jtcvs ) Copyright © 2010 The American Association for Thoracic Surgery Terms and Conditions


Download ppt "Salvage surgery for advanced non–small cell lung cancer after response to gefitinib  Tomoyuki Hishida, MD, Kanji Nagai, MD, Tetsuya Mitsudomi, MD, Kohei."

Similar presentations


Ads by Google